Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 21;8:206. doi: 10.3389/fcimb.2018.00206

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Kim, Shin and Shin.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Inhibition of MAP1981c-induced DC maturation via pharmacological inhibitors of MAPKs and NF-kB signals. Following pre-treatment with pharmacological inhibitors (ERK; U0126, JNK; SP600125, p38; SB203580, NF-kB; Bay11-7082) for 1 h, cells were stimulated with MAP1981c (5 μg/mL) for 24 h. (A, left panel) Analysis of surface markers (CD80 and CD86) on stimulated CD11c⁺ DCs by using flow cytometry. The histograms shown are representative of three independent experiments. (A, right panel) The MFI calculated from histograms is indicated as the mean ± SD of three independent experiments. **p < 0.01, ***p < 0.001 for the treatments compared with MAP1981c-treated DCs (MAP1981c). (B) The culture supernatants were analyzed for the amounts of TNF-α, IL-6, and IL-1β by using ELISA. *p < 0.05, **p < 0.01, ***p < 0.001 for the treatments compared with MAP1981c-treated DCs (MAP1981c). U; U0126, SP; SP600125, SB; SB203580, Bay; Bay11-7082.